Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immuneering (IMRX) Non Operating Income (2021 - 2026)

Immuneering's Non Operating Income history spans 6 years, with the latest figure at $513735.0 for Q1 2026.

  • On a quarterly basis, Non Operating Income changed N/A to $513735.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $825400.0, a 261.29% increase, with the full-year FY2025 number at $311665.0, down 29.41% from a year prior.
  • Non Operating Income came in at $513735.0 for Q1 2026, up from $311665.0 in the prior quarter.
  • The five-year high for Non Operating Income was $513735.0 in Q1 2026, with the low at -$103218.0 in Q1 2022.
  • Historically, Non Operating Income has averaged $201286.1 across 5 years, with a median of $181615.0 in 2023.
  • Biggest five-year swings in Non Operating Income: skyrocketed 1593.82% in 2022 and later plummeted 94.86% in 2024.
  • Year by year, Non Operating Income stood at $223278.0 in 2022, then surged by 107.97% to $464352.0 in 2023, then tumbled by 80.31% to $91430.0 in 2024, then soared by 240.88% to $311665.0 in 2025, then skyrocketed by 64.84% to $513735.0 in 2026.
  • Business Quant data shows Non Operating Income for IMRX at $513735.0 in Q1 2026, $311665.0 in Q4 2025, and $91430.0 in Q4 2024.